Literature DB >> 1984766

Systemic lupus erythematosus in a boy with chronic granulomatous disease: case report and review of the literature.

S Manzi1, A H Urbach, A B McCune, H A Altman, S S Kaplan, T A Medsger, R Ramsey-Goldman.   

Abstract

We describe a patient with X-linked chronic granulomatous disease (CGD) who developed systemic lupus erythematosus, which was characterized by photosensitivity, malar rash, glomerulonephritis, leukopenia, hypocomplementemia, antinuclear antibodies, and anti-double-stranded DNA antibodies, at age 3. The patient's mother is an asymptomatic carrier of CGD, and her other son (the patient's half-brother) also has CGD. Neither the mother nor the brother has clinical or serologic evidence of systemic lupus erythematosus. Previous cases of discoid lupus-like skin lesions have been reported both in carriers and in patients with CGD. Our patient represents the first reported case of an individual with convincing clinical, serologic, and pathologic evidence of systemic lupus erythematosus. The association between defective host defense mechanisms and autoimmune phenomena has been described previously in patients with Job's syndrome and in patients with B cell and T cell deficiency disorders, including the acquired immunodeficiency syndrome. The relationship between the known leukocyte defects in CGD and the pathogenesis of a lupus-like illness is unclear.

Entities:  

Mesh:

Year:  1991        PMID: 1984766     DOI: 10.1002/art.1780340116

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  19 in total

Review 1.  At the Bench: Neutrophil extracellular traps (NETs) highlight novel aspects of innate immune system involvement in autoimmune diseases.

Authors:  Peter C Grayson; Mariana J Kaplan
Journal:  J Leukoc Biol       Date:  2015-10-02       Impact factor: 4.962

2.  Reply.

Authors:  R Hal Scofield; Rohan Sharma; Valerie M Harris
Journal:  Arthritis Rheumatol       Date:  2018-02-22       Impact factor: 10.995

3.  Advances in treatment for chronic granulomatous disease.

Authors:  Elizabeth M Kang; Harry L Malech
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

Review 4.  Chronic granulomatous disease.

Authors:  Dirk Roos
Journal:  Br Med Bull       Date:  2016-03-16       Impact factor: 4.291

5.  Decreased STAT5 phosphorylation and GATA-3 expression in NOX2-deficient T cells: role in T helper development.

Authors:  Kristen E Shatynski; Haiyan Chen; Jaeyul Kwon; Mark S Williams
Journal:  Eur J Immunol       Date:  2012-10-01       Impact factor: 5.532

6.  Recurrent erythematous plaques on sun-exposed sites in an African American boy with chronic granulomatous disease.

Authors:  Mamina M Turegano; Chyi-Chia R Lee; Harry L Malech; Suk S De Ravin; Edward W Cowen; Isaac Brownell
Journal:  J Am Acad Dermatol       Date:  2014-03       Impact factor: 11.527

7.  Chronic granulomatous disease as a risk factor for autoimmune disease.

Authors:  Suk See De Ravin; Nora Naumann; Edward W Cowen; Julia Friend; Dianne Hilligoss; Martha Marquesen; James E Balow; Karyl S Barron; Maria L Turner; John I Gallin; Harry L Malech
Journal:  J Allergy Clin Immunol       Date:  2008-09-26       Impact factor: 10.793

8.  Host defense molecule polymorphisms influence the risk for immune-mediated complications in chronic granulomatous disease.

Authors:  C B Foster; T Lehrnbecher; F Mol; S M Steinberg; D J Venzon; T J Walsh; D Noack; J Rae; J A Winkelstein; J T Curnutte; S J Chanock
Journal:  J Clin Invest       Date:  1998-12-15       Impact factor: 14.808

9.  NADPH oxidase inhibits the pathogenesis of systemic lupus erythematosus.

Authors:  Allison M Campbell; Michael Kashgarian; Mark J Shlomchik
Journal:  Sci Transl Med       Date:  2012-10-24       Impact factor: 17.956

10.  Peptidylarginine deiminase inhibition disrupts NET formation and protects against kidney, skin and vascular disease in lupus-prone MRL/lpr mice.

Authors:  Jason S Knight; Venkataraman Subramanian; Alexander A O'Dell; Srilakshmi Yalavarthi; Wenpu Zhao; Carolyne K Smith; Jeffrey B Hodgin; Paul R Thompson; Mariana J Kaplan
Journal:  Ann Rheum Dis       Date:  2014-08-07       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.